Literature DB >> 3132637

Long-term prognosis in malignant or accelerated hypertension.

C Guerin1, R Gonthier, F C Berthoux.   

Abstract

In 51 consecutive patients with malignant hypertension collected from 1976 to 1981 we have analysed patient and kidney survival at 5 years and at last follow-up. The patients were 41 men, 10 women, mean age 53 years, with a stage III (63%) or stage IV (27%) fundi and a diastolic blood pressure (BP) greater than 130 mmHg. The hypertension was primary in 26, renovascular in 17 and secondary to bilateral nephropathy in eight. At 5-years follow-up, the patient and kidney survival rates were respectively 72.5% and 47%. At last follow-up, 18 patients had died (35%) and 18 additional patients require dialysis (renal death = 70%). The principal causes of death related to terminal renal failure and/or dialysis. Initial involvement of heart (27%) and brain (35%) led to a few more deaths. Blood pressure control reduced consequences for the heart and brain but not for the kidney. Patients at higher risk are those with serum creatinine greater than 200 mumol/l on admission.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132637

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Šárka Jíchová; Libor Kopkan; Zuzana Husková; Šárka Doleželová; Jan Neckář; Petr Kujal; Zdenka Vernerová; Herbert J Kramer; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Rami N Reddy; John R Falck; John D Imig; Luděk Červenka
Journal:  J Hypertens       Date:  2016-10       Impact factor: 4.844

2.  Malignant hypertension with thrombotic microangiopathy and persistent acute kidney injury (AKI).

Authors:  Chike Nzerue; Kemi Oluwole; David Adejorin; Paisit Paueksakon; Richard Fremont; Richmond Akatue; Marquetta Faulkner
Journal:  Clin Kidney J       Date:  2014-11-13

3.  20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Lenka Sedláková; Soňa Kikerlová; Zuzana Husková; Lenka Červenková; Věra Čertíková Chábová; Josef Zicha; John R Falck; John D Imig; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Vojtěch Krátký; Luděk Červenka; Libor Kopkan
Journal:  Biosci Rep       Date:  2018-09-12       Impact factor: 3.840

4.  Characteristics and Outcome of Biopsy-proven Malignant Hypertension with Severe Kidney Injury: A Retrospective Study.

Authors:  Satish Haridasan; P S Priyamvada; Dhanin Puthiyottil; Arjun Pradeep; Sreejith Parameswaran; B H Srinivas; Rajesh Nachiappa Ganesh
Journal:  Indian J Nephrol       Date:  2021-04-10

5.  Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study.

Authors:  Fouad Amraoui; Sarah Bos; Liffert Vogt; Bert-Jan van den Born
Journal:  BMC Nephrol       Date:  2012-07-30       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.